Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ.

J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.

2.

Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.

Yoshida H, Kimura A, Fukaya T, Sekiya T, Morita R, Shichita T, Inoue H, Yoshimura A.

Biochem Biophys Res Commun. 2012 Feb 10;418(2):234-40. doi: 10.1016/j.bbrc.2011.12.156. Epub 2012 Jan 9.

PMID:
22252297
3.

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

Tanaka Y, Maeshima K, Yamaoka K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i70-4. doi: 10.1136/annrheumdis-2011-200595. Erratum in: Ann Rheum Dis. 2013 Jan;72(1):156. Maeshima, Y [corrected to Maeshima, K].

PMID:
22460142
4.

Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.

Stevenson W, Sadrai Z, Hua J, Kodati S, Huang JF, Chauhan SK, Dana R.

Cornea. 2014 Feb;33(2):177-83. doi: 10.1097/ICO.0000000000000019.

PMID:
24342887
5.

Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis.

Mus AM, Cornelissen F, Asmawidjaja PS, van Hamburg JP, Boon L, Hendriks RW, Lubberts E.

Arthritis Rheum. 2010 Apr;62(4):1043-50. doi: 10.1002/art.27336.

6.

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.

Tanaka Y, Yamaoka K.

Mod Rheumatol. 2013 May;23(3):415-24. doi: 10.1007/s10165-012-0799-2. Epub 2012 Dec 5. Review.

PMID:
23212593
7.

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.

Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y.

Ann Rheum Dis. 2014 Dec;73(12):2192-8. doi: 10.1136/annrheumdis-2013-203756. Epub 2013 Sep 6.

PMID:
24013646
8.

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, Truitt T, Slade M, Lukacs C, Hermann J, Zhou M, Lucas M, Narula S, DeMartino J, Tan SL.

Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329.

9.

Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.

Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, Kishore N.

J Pharmacol Exp Ther. 2014 Jan;348(1):165-73. doi: 10.1124/jpet.113.209304. Epub 2013 Nov 11.

10.

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.

Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P.

Arthritis Res Ther. 2008;10(1):R14. doi: 10.1186/ar2365. Epub 2008 Jan 30.

11.

Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.

Yarilina A, Xu K, Chan C, Ivashkiv LB.

Arthritis Rheum. 2012 Dec;64(12):3856-66. doi: 10.1002/art.37691.

12.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K.

J Immunol. 2010 May 1;184(9):5298-307. doi: 10.4049/jimmunol.0902819. Epub 2010 Apr 2.

13.

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y.

Arthritis Rheum. 2012 Jun;64(6):1790-8. doi: 10.1002/art.34329. Epub 2011 Dec 6.

14.

Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo.

Jaen O, Rullé S, Bessis N, Zago A, Boissier MC, Falgarone G.

Immunology. 2009 Jan;126(1):35-44. doi: 10.1111/j.1365-2567.2008.02875.x. Epub 2008 Aug 27.

15.

CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.

West K.

Curr Opin Investig Drugs. 2009 May;10(5):491-504. Review. Erratum in: Curr Opin Investig Drugs. 2009 Sep;10(9):1004-6. Dosage error in article text.

PMID:
19431082
16.

EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity.

Yun TJ, Harning EK, Giza K, Rabah D, Li P, Arndt JW, Luchetti D, Biamonte MA, Shi J, Lundgren K, Manning A, Kehry MR.

J Immunol. 2011 Jan 1;186(1):563-75. doi: 10.4049/jimmunol.1000222. Epub 2010 Dec 3.

17.

VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.

Mahajan S, Hogan JK, Shlyakhter D, Oh L, Salituro FG, Farmer L, Hoock TC.

J Pharmacol Exp Ther. 2015 May;353(2):405-14. doi: 10.1124/jpet.114.221176. Epub 2015 Mar 11.

PMID:
25762693
18.

Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.

Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.

Arthritis Res. 1999;1(1):81-91. Epub 1999 Oct 26.

19.

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y, Bollinger CS, Bansal PN, Wellen JW, Wilkie DP, Bailey SA, Symanowicz PT, Hegen M, Head RD, Kishore N, Mbalaviele G, Meyer DM.

Arthritis Rheum. 2012 Nov;64(11):3531-42. doi: 10.1002/art.34649.

20.

An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells.

Kamiya S, Owaki T, Morishima N, Fukai F, Mizuguchi J, Yoshimoto T.

J Immunol. 2004 Sep 15;173(6):3871-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk